Bhaskar Chaudhuri Sells Shares of TARS

On June 12, 2026, Bhaskar Chaudhuri sold 2,954 shares of TARS. This transaction wasn't part of a pre-planned sale and occurred with the stock trading at $61.85.

Other Institutional Activity in TARS

DEEP TRACK CAPITAL, LP increased its stake in TARS by 595,966 shares, bringing its total to 3.6 million shares worth about $252.54 million. BLACKROCK, INC. reduced its holdings by 237,945 shares, ending with 3,552,612 shares valued at approximately $249.22 million. Meanwhile, RTW INVESTMENTS, LP added 10,705 shares, resulting in a total of 3,346,025 shares worth $234.72 million. PARADIGM BIOCAPITAL ADVISORS LP maintained its position, holding steady at 2,562,154 shares, valued at $179.74 million. JANUS HENDERSON GROUP PLC grew its holdings by 310,638 shares to 2,240,963 shares, valued at $157.22 million.

Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.

Several insiders were active on June 12, 2026. Bhaskar Chaudhuri sold 2,954 shares. Wendy Yarno bought and then sold 2,954 shares on the same day. William Link, PhD, also purchased 2,954 shares, while Scott Morrison and Andrew Goldberg each sold 2,954 shares. None of these transactions were under pre-planned trading programs.

Analysts Set New Price Targets

On May 4, 2026, HC Wainwright & Co. reiterated its buy rating for TARS with a price target of $88. Earlier in the year, Oppenheimer and Guggenheim maintained their buy ratings with targets of $105 and $90, respectively, on February 25, 2026. Barclays and Mizuho initiated coverage with buy ratings and targets of $100 in late 2025.

Bottom Line

Insider activity at TARS shows a mix of buying and selling, with Bhaskar Chaudhuri among those selling shares in June 2026. Institutional investors like DEEP TRACK CAPITAL are increasing their stakes, suggesting continued interest in the company. Analysts maintain positive outlooks with reiterated buy ratings and high price targets, reflecting confidence in TARS's future prospects.